Literature DB >> 24476739

Triple-negative breast cancer: what is known about it?

Lisa L Ferguson1, Britne Curran1, Mary Martinez1, Peggy Mancuso1.   

Abstract

Triple-negative breast cancer (TNBC) is considered a rare diagnosis. This malignancy targets a specific population of women and has risk factors differing from those of other breast cancers. TNBC exhibits distinct pathologic features that result in aggressive metastasis and poor prognosis. Pathologically, TNBC cancer cells are characterized by negative receptors for progesterone and estrogen and by the lack of over-expression of human epidermal growth factor receptor 2, which limits chemotherapeutic treatment options for women with TNBC. Nurses can assist in early detection by offering patient education about the little known risk factors for TNBC. Psychosocial issues can overwhelm patients diagnosed with breast cancer. This article provides suggestions for nurses as they guide women who are experiencing an atypical breast cancer diagnosis with an uncertain prognosis and limited treatment options.

Entities:  

Keywords:  breast cancer; chemotherapy; patient/public education; psychosocial aspects; surgery

Mesh:

Year:  2014        PMID: 24476739     DOI: 10.1188/14.CJON.E6-E11

Source DB:  PubMed          Journal:  Clin J Oncol Nurs        ISSN: 1092-1095            Impact factor:   1.027


  3 in total

1.  Bufalin Induces Programmed Necroptosis in Triple-Negative Breast Cancer Drug-Resistant Cell Lines through RIP1/ROS-Mediated Pathway.

Authors:  Xiao-Dan Liu; Cheng-Yang Song; Cui-Cui Kong; Xin Tian
Journal:  Chin J Integr Med       Date:  2021-11-26       Impact factor: 2.626

2.  Computational identification of multi-omic correlates of anticancer therapeutic response.

Authors:  Lindsay C Stetson; Taylor Pearl; Yanwen Chen; Jill S Barnholtz-Sloan
Journal:  BMC Genomics       Date:  2014-10-27       Impact factor: 3.969

3.  MicroRNA-129-1-3p Represses the Progression of Triple-Negative Breast Cancer by Targeting the GRIN2D Gene.

Authors:  Qi Li; Zehui Gu; Qi Tan; Liqun Ren; Suxian Chen
Journal:  Biomed Res Int       Date:  2022-03-07       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.